英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
189633查看　189633　在百度字典中的解释百度英翻中〔查看〕
189633查看　189633　在Google字典中的解释Google英翻中〔查看〕
189633查看　189633　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Tislelizumab Combined With Induction Chemotherapy and . . .
    To evaluate the efficacy and safety of adding tislelizumab to induction chemotherapy and concurrent chemoradiotherapy (CRT), with or without maintenance immunotherapy, in patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC)
  • Drugs Approved for Esophageal Cancer - NCI
    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for esophageal cancer, including gastroesophageal junction cancer The list includes generic names and brand names
  • BeOne Medicines Tevimbra (Tislelizumab-jsgr) Monograph for . . .
    Tevimbra (tislelizumab-jsgr) is an FDA-approved cancer treatment option for people with esophageal cancer and gastric cancer The treatment can be used in varying doses in two-, three-, or four-week intervals for adults as a first-line or single-agent treatment of unresectable or metastatic esophageal squamous cell carcinoma and in combination with platinum and fluoropyrimidine-based
  • label - accessdata. fda. gov
    INDICATIONS AND USAGE 1 1 Esophageal Cancer TEVIMBRA, as a single agent, is indicated for the treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor
  • FDA Approves Tislelizumab for Previously Treated Patients . . .
    The FDA is also reviewing biologics license applications for tislelizumab as a first-line treatment of unresectable, recurrent, locally advanced, or metastatic esophageal squamous cell carcinoma and locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
  • FDA Approves Tislelizumab for Esophageal Squamous Cell Carcinoma
    The U S Food and Drug Administration (FDA) approved tislelizumab-jsgr (Tevimbra) in combination with platinum-based chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 Drugmaker BeiGene announced the approval in a March 4 news release
  • NCCN Flash Update: Guideline Update for Esophageal and . . .
    The Version 3 2025 update adds tislelizumab-based regimens as preferred first-line treatments and introduces new dosing schedules for PD-L1–positive esophageal squamous cell carcinoma
  • Kato Breaks Down FDA Approval of Tislelizumab in Esophageal . . .
    Tislelizumab is a PD-1 antibody made in China The trial evaluated tislelizumab in combination with platinum-containing chemotherapy regimens The RATIONALE-306 trial aimed to validate the additive effect of tislelizumab to baseline chemotherapy and its role in the first-line treatment of esophageal squamous cell carcinoma
  • Tislelizumab: Side Effects, Uses, Dosage, Interactions, Warnings
    Tislelizumab is a prescription medication indicated for: Esophageal Cancer In combination with platinum-containing chemotherapy as first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express programmed death- (Ligand) 1 [PD- (L)1] (greater than or equal to 1) As a single agent in adults with unresectable or metastatic ESCC
  • FDA Approves Second-Line Tislelizumab Monotherapy in . . .
    Data from the phase 3 RATIONALE 302 trial (NCT03430843) supported the FDA approval of tislelizumab-jsgr as a treatment for those with previously treated unresectable or metastatic esophageal squamous cell carcinoma





中文字典-英文字典  2005-2009